Prosecution Insights
Last updated: April 19, 2026

Ionis Pharmaceuticals Inc.

26 pending office actions

Portfolio Summary

26
Total Pending OAs
12
Final Rejections
14
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18585339 GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF BEANE, RANDALL L 1654 Final Rejection Feb 23, 2024
18548711 PURIFICATION METHODS FOR OLIGOMERIC COMPOUNDS KRISHNAN, GANAPATHY 1693 Non-Final OA Sep 01, 2023
18546462 COMPOUNDS AND METHODS FOR REDUCING NLRP3 EXPRESSION CHONG, KIMBERLY 1636 Non-Final OA Aug 15, 2023
18263194 COMPOUNDS AND METHODS FOR MODULATING HUNTINGTIN TATGE, LEXUS MARC 1637 Non-Final OA Jul 27, 2023
18262438 COMPOUNDS AND METHODS FOR REDUCING DUX4 EXPRESSION KONOPKA, CATHERINE ANNE 1635 Non-Final OA Jul 21, 2023
18247567 METHODS FOR REDUCING APOCIII EXPRESSION POLIAKOVA-GEORGAN, EKATERINA 1637 Non-Final OA Mar 31, 2023
18158290 COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION MCGARRY, SEAN 1635 Non-Final OA Jan 23, 2023
18001848 COMPOUNDS AND METHODS FOR MODULATING PMP22 POLIAKOVA-GEORGAN, EKATERINA 1637 Final Rejection Dec 14, 2022
18001241 COMPOUNDS AND METHODS FOR REDUCING MSH3 EXPRESSION SHIN, DANA H 1635 Non-Final OA Dec 08, 2022
17998141 CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF ROSSI, JULIA ANNE LORRAIN 1615 Non-Final OA Nov 07, 2022
17802324 COMPOUNDS AND METHODS FOR MODULATING SCN1A EXPRESSION POLIAKOVA-GEORGAN, EKATERINA 1637 Non-Final OA Aug 25, 2022
17800785 METHODS FOR REDUCING HTT EXPRESSION CHONG, KIMBERLY 1636 Non-Final OA Aug 18, 2022
17721765 Compositions for Modulating C9ORF72 Expression PERSONS, JENNA L 1637 Final Rejection Apr 15, 2022
17611765 SYNTHESIS OF OLIGOMERIC COMPOUNDS COMPRISING PHOSPHOROTHIOATE DIESTER AND PHOSPHODIESTER LINKAGES LEE, HOI YAN NMN 1693 Final Rejection Nov 16, 2021
17611780 ANGIOTENSIN II TYPE 1 RECEPTOR TARGETED OLIGONUCLEOTIDES AND USES THEREOF ARIETI, RUTH SOPHIA 1635 Final Rejection Nov 16, 2021
17522594 COMPOUNDS AND METHODS FOR REDUCING SNCA EXPRESSION MCLEOD, AFRICA MHAIRIE 1635 Non-Final OA Nov 09, 2021
17481679 COMPOSITIONS AND METHODS FOR MODULATING TAU EXPRESSION MCGARRY, SEAN 1635 Non-Final OA Sep 22, 2021
17432237 COMPOUNDS AND METHODS FOR REDUCING ATXN3 EXPRESSION VANHORN, ABIGAIL LOUISE 1636 Final Rejection Aug 19, 2021
17389599 MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION ARIETI, RUTH SOPHIA 1635 Final Rejection Jul 30, 2021
17424672 COMPOUNDS AND METHODS FOR REDUCING APP EXPRESSION PERSONS, JENNA L 1637 Final Rejection Jul 21, 2021
17372173 MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) POPULATIONS POLIAKOVA-GEORGAN, EKATERINA 1637 Final Rejection Jul 09, 2021
17365307 OLIGOMER-CONJUGATE COMPLEXES AND THEIR USE TRAN, CHRISTINA L 1637 Final Rejection Jul 01, 2021
17416108 MODULATORS OF HSD17B13 EXPRESSION ANGELL, JON E 1637 Final Rejection Jun 18, 2021
17291199 COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING AMYOTROPHIC LATERAL SCLEROSIS QIAN, CELINE X 1637 Non-Final OA May 04, 2021
16951449 Compounds and Methods for Modulation of Transcript Processing VYAS, KEYUR ANILKUMAR 1637 Final Rejection Nov 18, 2020
16948435 Compositions for Modulating C9ORF72 Expression ANGELL, JON E 1637 Non-Final OA Sep 18, 2020

Managing Ionis Pharmaceuticals Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month